Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Breast Neoplasms 3Drug-Related Side Effects and Adverse Reactions 2Breast Neoplasms, Male 2Rectal Neoplasms 1Ovarian Neoplasms 1Hand-Foot Syndrome 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

pembrolizumab 42Paclitaxel 26Cyclophosphamide 25Carboplatin 23olaparib 21Nivolumab 16fludarabine 15Docetaxel 13aldesleukin 12Gemcitabine 11Fulvestrant 11veliparib 9Bevacizumab 9sargramostim 8palbociclib 8durvalumab 8Trastuzumab 8Magnetic Resonance Spectroscopy 8liposomal doxorubicin 7atezolizumab 7Surveys and Questionnaires 7Ipilimumab 7Blood Specimen Collection 7niraparib 6avelumab 6Taxes 6Specimen Handling 6Interleukin-2 6Fluorouracil 6Cisplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × Pyridoxine × Breast × Clear all
NCT00245050 2011-12-30

Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer

Case Comprehensive Cancer Center

Phase 3 Completed
34 enrolled 9 charts
BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Breast Neoplasms, Male, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡